Gender differences in the association between discharge hemoglobin and 12-month mortality after acute myocardial

Lauren E Thompson1,2, Frederick A Masoudi1,2, Kensey L Gosch3

  • 1Division of Cardiology, Aurora, Colorado.

Clinical Cardiology
|December 17, 2017
PubMed

Insights

Anemia at discharge after acute myocardial infarction (AMI) is linked to worse outcomes for both women and men. This association is linear, meaning any drop in hemoglobin levels indicates a higher risk of mortality within 12 months.

Area of Science:

  • Cardiology
  • Hematology
  • Clinical Outcomes Research

Background:

  • Anemia at discharge following acute myocardial infarction (AMI) is a known predictor of poor prognosis.
  • However, the influence of gender on this relationship and the existence of a specific hemoglobin (Hb) threshold remain unclear.

Purpose of the Study:

  • To investigate the association between discharge hemoglobin (Hb) levels and 12-month mortality in patients with AMI.
  • To determine if this relationship differs between women and men or exhibits a nonlinear pattern.

Main Methods:

  • Utilized data from the TRIUMPH registry (2005-2008) for 4243 AMI patients.
  • Employed multivariable models to assess the link between discharge Hb and 12-month mortality, testing for gender interactions.
  • Used restricted cubic splines to evaluate the linearity of the Hb-mortality relationship.

Main Results:

  • Lower discharge Hb was independently associated with increased 12-month mortality (P < 0.05).
  • The association between Hb decline and mortality was similar in women and men (HR: ~1.24-1.25 per 1-g/dL decrease; P for gender interaction = 0.99).
  • The relationship between discharge Hb and mortality was linear, with no significant nonlinear spline term (P = 0.12).

Conclusions:

  • Discharge anemia in AMI patients is similarly linked to increased 12-month mortality in both genders.
  • The relationship is linear, indicating that any reduction in hemoglobin levels at discharge is associated with adverse outcomes.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
934
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
294